News
PPTDF
5.98
NaN%
--
PeptiDream announces initiation of Phase 1 clinical trial of AK1940
TipRanks · 04/20 14:23
Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations
Seeking Alpha · 04/16 09:15
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides
Seeking Alpha · 04/15 17:42
PeptiDream downgraded to Neutral from Buy at Citi
TipRanks · 03/12 10:22
Citi Remains a Hold on Peptidream (PPTDF)
TipRanks · 03/12 10:18
SBI Securities Reaffirms Their Buy Rating on Peptidream (PPTDF)
TipRanks · 03/02 10:27
PeptiDream Earnings Call: Pipeline Momentum, Deal Delays
TipRanks · 02/18 00:17
Goldman Sachs Reaffirms Their Buy Rating on Peptidream (PPTDF)
TipRanks · 02/17 10:25
Nomura Sticks to Their Buy Rating for Peptidream (PPTDF)
TipRanks · 02/17 10:16
Goldman Sachs Remains a Buy on Peptidream (PPTDF)
TipRanks · 12/03/2025 15:27
Weekly Report: what happened at PPTDF last week (0908-0912)?
Weekly Report · 09/15/2025 09:53
Weekly Report: what happened at PPTDF last week (0901-0905)?
Weekly Report · 09/08/2025 09:54
Weekly Report: what happened at PPTDF last week (0825-0829)?
Weekly Report · 09/01/2025 09:52
Weekly Report: what happened at PPTDF last week (0818-0822)?
Weekly Report · 08/25/2025 09:55
Weekly Report: what happened at PPTDF last week (0811-0815)?
Weekly Report · 08/18/2025 09:53
Weekly Report: what happened at PPTDF last week (0804-0808)?
Weekly Report · 08/11/2025 09:55
Weekly Report: what happened at PPTDF last week (0728-0801)?
Weekly Report · 08/04/2025 09:57
Weekly Report: what happened at PPTDF last week (0721-0725)?
Weekly Report · 07/28/2025 09:57
Weekly Report: what happened at PPTDF last week (0714-0718)?
Weekly Report · 07/21/2025 09:53
Weekly Report: what happened at PPTDF last week (0707-0711)?
Weekly Report · 07/14/2025 09:56
More
Webull provides a variety of real-time PPTDF stock news. You can receive the latest news about Peptidream through multiple platforms. This information may help you make smarter investment decisions.
About PPTDF
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).